Skip to content

Study · Observational study · n = 40,768 · 2025

10 results

Semaglutide versus other GLP-1 receptor agonists in patients with MASLD.

Kuo CC, Li CH, Chuang MH, Huang PY, Kuo HT, Lai CC

Hepatology communications19 Jun 2025Cited by 15 (Europe PMC)

PMID40536520 (opens in a new tab)PMCIDPMC12180814 (opens in a new tab)DOI10.1097/hc9.0000000000000747 (opens in a new tab)PepBankPUB-40536520
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with MASLD, semaglutide was associated with a 14% lower risk of the primary composite outcome than other GLP-1RAs (31.8 vs. 36.6 events per 10,000 person-years; adjusted HR, 0.86; 95% CI: 0.80-0.93).

    In plain wordsIn people with MASLD, semaglutide was linked to lower composite-outcome risk than other GLP-1 medicines.

    Peptide
    Semaglutide
    Outcome
    DecreasePrimary composite outcome risk
    Study

    n = 40,768

    Comparator
    Other GLP-1RAs
    Analysis
    Primary
    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    Dose not stated

    Measurements

    Adjusted hazard ratio
    0.86
    semaglutide versus other GLP-1RAs
    95% CI
    0.8 to 0.93
    semaglutide versus other GLP-1RAs
    Reported risk reduction
    14%
    semaglutide versus other GLP-1RAs
    Event rate
    31.8 events per 10,000 person-years
    semaglutide
    Event rate
    36.6 events per 10,000 person-years
    other GLP-1RAs

    Source sentences

    Summary
    Compared to other GLP-1RAs, semaglutide was associated with a 14% lower risk of primary composite outcomes (31.8 vs. 36.6 events per 10,000 person-years; adjusted HR, 0.86; 95% CI: 0.80-0.93).
    4 context sentences
    Summary · context
    Using the TriNetX Research Network database, we conducted a retrospective cohort study of patients with MASLD newly prescribed GLP-1RAs between December 2017 and September 2023.
    Summary · context
    The primary outcome was a composite of all-cause mortality, major adverse cardiovascular events, major adverse kidney events, and major adverse liver outcomes.
    Summary · context
    Secondary outcomes included the individual components of the primary outcome.
    Summary · context
    After propensity score matching, 20,384 patients were included in each group.
  2. 02HumanObservational studyEfficacy outcome

    In patients with MASLD, semaglutide use was associated with lower all-cause mortality risk than other GLP-1RAs (aHR, 0.68; 95% CI: 0.59-0.80).

    In plain wordsIn people with MASLD, semaglutide use was linked to lower all-cause mortality risk than other GLP-1 medicines.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause mortality risk
    Study

    n = 40,768

    Comparator
    Other GLP-1RAs
    Analysis
    Secondary
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Adjusted hazard ratio
    0.68
    semaglutide versus other GLP-1RAs; mortality
    95% CI
    0.59 to 0.8
    semaglutide versus other GLP-1RAs; mortality

    Source sentences

    Summary
    Semaglutide users showed significantly reduced risks of all-cause mortality (aHR, 0.68; 95% CI: 0.59-0.80) and major adverse liver outcomes (aHR, 0.79; 95% CI: 0.66-0.94).
    4 context sentences
    Summary · context
    Using the TriNetX Research Network database, we conducted a retrospective cohort study of patients with MASLD newly prescribed GLP-1RAs between December 2017 and September 2023.
    Summary · context
    The primary outcome was a composite of all-cause mortality, major adverse cardiovascular events, major adverse kidney events, and major adverse liver outcomes.
    Summary · context
    Secondary outcomes included the individual components of the primary outcome.
    Summary · context
    After propensity score matching, 20,384 patients were included in each group.
  3. 03HumanObservational studyEfficacy outcome

    In patients with MASLD, semaglutide use was associated with lower major adverse liver outcome risk than other GLP-1RAs (aHR, 0.79; 95% CI: 0.66-0.94).

    In plain wordsIn people with MASLD, semaglutide use was linked to lower major liver-outcome risk than other GLP-1 medicines.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor adverse liver outcome risk
    Study

    n = 40,768

    Comparator
    Other GLP-1RAs
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    Adjusted hazard ratio
    0.79
    semaglutide versus other GLP-1RAs; liver outcomes
    95% CI
    0.66 to 0.94
    semaglutide versus other GLP-1RAs; liver outcomes

    Source sentences

    Summary
    Semaglutide users showed significantly reduced risks of all-cause mortality (aHR, 0.68; 95% CI: 0.59-0.80) and major adverse liver outcomes (aHR, 0.79; 95% CI: 0.66-0.94).
    4 context sentences
    Summary · context
    Using the TriNetX Research Network database, we conducted a retrospective cohort study of patients with MASLD newly prescribed GLP-1RAs between December 2017 and September 2023.
    Summary · context
    The primary outcome was a composite of all-cause mortality, major adverse cardiovascular events, major adverse kidney events, and major adverse liver outcomes.
    Summary · context
    Secondary outcomes included the individual components of the primary outcome.
    Summary · context
    After propensity score matching, 20,384 patients were included in each group.
  4. 04HumanObservational studyEfficacy outcome

    In patients with MASLD, semaglutide was associated with lower hazard for an unspecified comparative clinical outcome than dulaglutide (published aHR 0.88, 95% CI 0.81 to 0.96); the analyzed subgroup N was unstated.

    In plain wordsIn MASLD cohorts, semaglutide was linked to lower hazard for the unspecified clinical outcome than dulaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHazard for unspecified comparative clinical outcome
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    Dose not stated

    Measurements

    Adjusted hazard ratio
    0.88
    semaglutide versus dulaglutide; unspecified clinical outcome
    95% CI
    0.81 to 0.96
    semaglutide versus dulaglutide; unspecified clinical outcome

    Source sentences

    Summary
    Comparative analyses showed superior outcomes with semaglutide versus dulaglutide (aHR, 0.88; 95% CI: 0.81-0.96) and liraglutide (aHR, 0.83; 95% CI: 0.71-0.97).
    2 context sentences
    Summary · context
    Using the TriNetX Research Network database, we conducted a retrospective cohort study of patients with MASLD newly prescribed GLP-1RAs between December 2017 and September 2023.
    Summary · context
    After propensity score matching, 20,384 patients were included in each group.
  5. 05HumanObservational studyEfficacy outcome

    In patients with MASLD, semaglutide was associated with lower hazard for an unspecified comparative clinical outcome than liraglutide (published aHR 0.83, 95% CI 0.71 to 0.97); the analyzed subgroup N was unstated.

    In plain wordsIn MASLD cohorts, semaglutide was linked to lower hazard for the unspecified clinical outcome than liraglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHazard for unspecified comparative clinical outcome
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    Dose not stated

    Measurements

    Adjusted hazard ratio
    0.83
    published semaglutide versus liraglutide orientation
    95% CI
    0.71 to 0.97
    published semaglutide versus liraglutide orientation

    Source sentences

    Summary
    Comparative analyses showed superior outcomes with semaglutide versus dulaglutide (aHR, 0.88; 95% CI: 0.81-0.96) and liraglutide (aHR, 0.83; 95% CI: 0.71-0.97).
    2 context sentences
    Summary · context
    Using the TriNetX Research Network database, we conducted a retrospective cohort study of patients with MASLD newly prescribed GLP-1RAs between December 2017 and September 2023.
    Summary · context
    After propensity score matching, 20,384 patients were included in each group.
  6. 06HumanObservational studyEfficacy outcome

    In patients with MASLD, liraglutide was associated with higher hazard for the unspecified comparative clinical outcome than semaglutide; the published semaglutide-versus-liraglutide aHR 0.83 (95% CI 0.71 to 0.97) is retained without inversion.

    In plain wordsIn MASLD cohorts, liraglutide was linked to higher hazard for the unspecified clinical outcome than semaglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseHazard for unspecified comparative clinical outcome
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    Dose not stated

    Measurements

    Adjusted hazard ratio
    0.83
    published semaglutide versus liraglutide orientation; not inverted
    95% CI
    0.71 to 0.97
    published semaglutide versus liraglutide orientation; not inverted

    Source sentences

    Summary
    Comparative analyses showed superior outcomes with semaglutide versus dulaglutide (aHR, 0.88; 95% CI: 0.81-0.96) and liraglutide (aHR, 0.83; 95% CI: 0.71-0.97).
    2 context sentences
    Summary · context
    Using the TriNetX Research Network database, we conducted a retrospective cohort study of patients with MASLD newly prescribed GLP-1RAs between December 2017 and September 2023.
    Summary · context
    After propensity score matching, 20,384 patients were included in each group.
  7. 07HumanObservational studyEfficacy outcome

    In retrospective MASLD cohorts, semaglutide comparative benefits were reported consistent across age strata; no stratum-specific coefficient, reference category, interaction test or analyzed N was stated.

    In plain wordsIn MASLD cohorts, semaglutide benefits were reported consistent across age groups; subgroup estimates and the exact reference were unstated.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedSemaglutide comparative-benefit consistency across age strata
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Benefits were consistent across subgroups, including age, sex, obesity status, and diabetes status.
    2 context sentences
    Summary · context
    Using the TriNetX Research Network database, we conducted a retrospective cohort study of patients with MASLD newly prescribed GLP-1RAs between December 2017 and September 2023.
    Summary · context
    Compared to other GLP-1RAs, semaglutide was associated with a 14% lower risk of primary composite outcomes (31.8 vs. 36.6 events per 10,000 person-years; adjusted HR, 0.86; 95% CI: 0.80-0.93).
  8. 08HumanObservational studyEfficacy outcome

    In retrospective MASLD cohorts, semaglutide comparative benefits were reported consistent across sex strata; no stratum-specific coefficient, reference category, interaction test or analyzed N was stated.

    In plain wordsIn MASLD cohorts, semaglutide benefits were reported consistent across sex groups; subgroup estimates and the exact reference were unstated.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedSemaglutide comparative-benefit consistency across sex strata
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Benefits were consistent across subgroups, including age, sex, obesity status, and diabetes status.
    2 context sentences
    Summary · context
    Using the TriNetX Research Network database, we conducted a retrospective cohort study of patients with MASLD newly prescribed GLP-1RAs between December 2017 and September 2023.
    Summary · context
    Compared to other GLP-1RAs, semaglutide was associated with a 14% lower risk of primary composite outcomes (31.8 vs. 36.6 events per 10,000 person-years; adjusted HR, 0.86; 95% CI: 0.80-0.93).
  9. 09HumanObservational studyEfficacy outcome

    In retrospective MASLD cohorts, semaglutide comparative benefits were reported consistent across obesity status strata; no stratum-specific coefficient, reference category, interaction test or analyzed N was stated.

    In plain wordsIn MASLD cohorts, semaglutide benefits were reported consistent across obesity status groups; subgroup estimates and the exact reference were unstated.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedSemaglutide comparative-benefit consistency across obesity status strata
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Benefits were consistent across subgroups, including age, sex, obesity status, and diabetes status.
    2 context sentences
    Summary · context
    Using the TriNetX Research Network database, we conducted a retrospective cohort study of patients with MASLD newly prescribed GLP-1RAs between December 2017 and September 2023.
    Summary · context
    Compared to other GLP-1RAs, semaglutide was associated with a 14% lower risk of primary composite outcomes (31.8 vs. 36.6 events per 10,000 person-years; adjusted HR, 0.86; 95% CI: 0.80-0.93).
  10. 10HumanObservational studyEfficacy outcome

    In retrospective MASLD cohorts, semaglutide comparative benefits were reported consistent across diabetes status strata; no stratum-specific coefficient, reference category, interaction test or analyzed N was stated.

    In plain wordsIn MASLD cohorts, semaglutide benefits were reported consistent across diabetes status groups; subgroup estimates and the exact reference were unstated.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedSemaglutide comparative-benefit consistency across diabetes status strata
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Benefits were consistent across subgroups, including age, sex, obesity status, and diabetes status.
    2 context sentences
    Summary · context
    Using the TriNetX Research Network database, we conducted a retrospective cohort study of patients with MASLD newly prescribed GLP-1RAs between December 2017 and September 2023.
    Summary · context
    Compared to other GLP-1RAs, semaglutide was associated with a 14% lower risk of primary composite outcomes (31.8 vs. 36.6 events per 10,000 person-years; adjusted HR, 0.86; 95% CI: 0.80-0.93).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.